Biomedical Policy · global
From Chips to Clinical Care: Taiwan’s Biomedical Policy Connects AI Drug Development and Smart Medical Devices
The 2026 Bio Taiwan Committee meeting outlined a path for collaboration between the semiconductor and healthcare sectors, spanning biomedical chips, health data and pharmaceutical quality monitoring; translating these efforts into patient benefits still hinges on clinical evidence and data governance.
Chip manufacturing and healthcare are two industries in which Taiwan has deep foundations. How to bring them together to address challenges in disease and care is becoming a new question for biomedical policy. At the Executive Yuan’s Bio Taiwan Committee (BTC) meeting, which opened on August 24, 2026, the government identified AI drug research and development, digital healthcare platforms and pharmaceutical supply resilience as policy priorities, seeking to extend its hardware strengths into research, manufacturing and clinical settings.
In its August 28 report, DIGITIMES characterized this industrial path in terms of AI drug discovery, smart medical devices and biomedical chips. According to the Central News Agency, supporting measures proposed by the Ministry of Economic Affairs cover cross-disciplinary AI applications, pharmaceutical supply chains, evidence of clinical benefits and overseas markets. This means that, beyond supporting technology development, policy must also help products generate evidence that healthcare providers are willing to adopt them on the basis of.
Biomedical chips are one of the more concrete elements. Chiu Chyou-huey, director-general of the Ministry of Economic Affairs’ Industrial Development Administration, said Taiwan would use established domestic processes, including CMOS and microelectromechanical systems (MEMS), to develop specialized processes for biomedical needs, while working with research institutes to develop common-reference chip designs. Plans also call for introducing AI into smart medical devices and pharmaceutical manufacturing to improve processes through real-time data collection and quality monitoring. These efforts lay the groundwork for research and production tools; their actual benefits still need to be validated in individual applications.
Another path begins with health data. In his keynote address at the meeting, Chi-Huey Wong proposed integrating National Health Insurance, human biobank and genomic data to establish an AI learning platform in which data remain within each institution, while also developing talent with both biomedical and AI expertise. The proposal brings different types of data into a shared learning framework, but the relevant reports did not specify the platform’s scale, particular disease tasks or validation results. It should currently be regarded as a proposal for research infrastructure.
How data are used also affects the boundaries of industry applications. The Executive Yuan’s meeting minutes indicate that the government hopes to make health information more widely available for noncommercial, nonprofit academic research. This direction cannot be interpreted directly as meaning that companies can already obtain data to develop products. How research and commercial uses will connect, and how access permissions, privacy protection and responsibilities will be arranged, still require clear institutional design.
Clinical validation therefore becomes an important part of the overall policy. Chiu noted that even after medical devices receive marketing authorization, they may still struggle to expand their markets without evidence of actual benefits. The government will support validation through funding and institutional matchmaking. For AI in healthcare, questions extend beyond model performance to whether it is reliable across different hospitals and patient populations, and whether it can improve diagnostic and treatment workflows or health outcomes.
The meeting presented a direction for development across government agencies. Publicly available information did not provide drug candidates, trial designs or human results sufficient to assess the effectiveness of any specific AI-developed new drug. From chips and data to medical products, Taiwan has proposed a more comprehensive vision for connecting these elements. Further progress will depend on whether these tools can generate testable evidence in clearly defined disease and care settings.